Epocrates Reports 2010 Fourth Quarter And Full-Year Financial Results And Provides 2011 Outlook
To participate in the live conference call and webcast, please dial 877-398-9481 (if dialing from within the U.S.) or 760-298-5095 (if dialing from outside the U.S.) using conference code 47269531 or visit the Investor Relations section of the company's web site at http://www.epocrates.com .
A replay of the conference call will be available approximately two hours after the completion of the conference call by dialing 800-642-1687 (if dialing from within the U.S.) or 706-645-9291 (if dialing from outside the U.S.) using conference code 47269531. The replay will be available for one week on the above number. A webcast replay will also be archived on the company's website for approximately 12 months.
About Epocrates, Inc.
Epocrates is a leading provider of mobile drug reference tools to healthcare professionals and interactive services to the healthcare industry. Epocrates' active user network currently has more than one million healthcare professionals, including more than 45 percent of U.S. physicians. Most commonly used on mobile devices at the point of care, the company's clinical products and services help healthcare professionals make more informed prescribing decisions, enhance patient safety and improve practice productivity. For more information about Epocrates, please visit www.epocrates.com .Epocrates, Epocrates EHR and DocAlert are trademarks of Epocrates, Inc., in the U.S. and other countries. Forward-Looking Statements Statements contained in this press release under the heading "Outlook for Full-Year 2011" and in Ms. Crane's quote regarding Epocrates being poised to deliver on its growth targets and strengthen its leadership, and opportunities for the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause Epocrates' actual results to be materially different than those expressed in or implied by Epocrates' forward-looking statements. For Epocrates, particular uncertainties and risks include, among others: unexpected delays in Epocrates delivering new products may occur, which would cause revenues not to be as Epocrates expects; market acceptance of new products may not be as Epocrates expects, which would cause revenues not to be as Epocrates expects; and the impact of competitive products and pricing may force Epocrates to decrease the price of its products. More detailed information on these and additional factors that could affect Epocrates' actual results are described in Epocrates' filings with the Securities and Exchange Commission, including its final prospectus filed with the Securities and Exchange Commission on February 2, 2011. Except as required by law, Epocrates undertakes no obligation to publicly update its forward-looking statements. Use of Non-GAAP Financial Measures To supplement Epocrates' condensed consolidated financial statements presented on a GAAP basis, Epocrates uses non-GAAP measures of gross margin, gross margin percentage, operating income, operating income percentage, net income and net income per share, which are adjusted to exclude certain costs, expenses, gains and losses Epocrates believes appropriate to enhance an overall understanding of its past financial performance and also its prospects for the future. These adjustments to current period GAAP results are made with the intent of providing both management and investors a more complete understanding of Epocrates' underlying operational results and trends and its marketplace performance. In addition, these adjusted non-GAAP results are among the information management uses as a basis for planning and forecasting of future periods. The presentation of this additional information is not meant to be considered in isolation or as a substitute for results prepared in accordance with generally accepted accounting principles in the United States of America.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Check Out Our Best Services for Investors
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.